small-molecule and a multitarget tki anlotinib (MultiTarget Pharmaceuticals)
90
Structured Review
MultiTarget Pharmaceuticals
small-molecule and a multitarget tki anlotinib
Small Molecule And A Multitarget Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+tkis/anlotinib/pmc12198539-51-6-4
Average 90 stars, based on 1 article reviews
Small Molecule And A Multitarget Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+tkis/anlotinib/pmc12198539-51-6-4
Average 90 stars, based on 1 article reviews
small-molecule and a multitarget tki anlotinib - by Bioz Stars,
2026-11
90/100 stars
Images
1) Product Images from "Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis"
Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis
Journal: Therapeutic Advances in Medical Oncology
doi: 10.1177/17588359251348310
Figure Legend Snippet: Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
Techniques Used:
Figure Legend Snippet: HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.
Techniques Used:
Figure Legend Snippet: Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.
Techniques Used:
Related Articles
other:Article Title: Second-line treatment in renal cell carcinoma: clinical experience and decision making Article Snippet: As a whole, adverse events associated with the administration of Article Title: Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex. Article Snippet: Because reactivation of the PI3K-AKT-mTOR pathway and MAPK pathway is critical for the acquired resistance of Activity Assay:Article Title: Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Article Snippet: Introduction: Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly employed for the treatment of various cancers in clinical practice.. This study aimed to systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors for advanced hepatocellular carcinoma (HCC).. Methods: PubMed, EMBASE, Cochrane library, Web of Science, and Abstracts of American Society of Clinical Oncology proceedings databases were searched. Diffusion-based Assay:Article Title: Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model Article Snippet: .. Another approach is giving low-dose AAGs continuously, especially |
